Rapid Micro Biosystems, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Rapid Micro Biosystems develops and sells its Growth Direct automated microbial quality-control systems, consumables, software, and related services for pharmaceutical and other regulated manufacturing. Financial statements are unaudited.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $6.1M | $4.7M | $16.2M | $12.8M |
| Operating loss | $14.4M | $16.9M | $44.4M | $46.0M |
| Net loss | $13.4M | $16.3M | $41.3M | $44.4M |
| Net loss per share | $0.31 | $0.38 | $0.96 | $1.05 |
| Operating cash used | Not provided for quarter | Not provided for quarter | $35.6M | $46.9M |
- Q3 revenue grew 29.7% year over year: product revenue rose 30.9% to $4.2M and service revenue rose 27.1% to $1.9M. Nine-month revenue increased 26.8%.
- Recurring product and service revenue was $3.4M in Q3, up 17.3%; it represented 55.5% of quarterly revenue versus 61.4% a year earlier. Nine-month recurring revenue was $10.3M, up 27.1%.
- Gross loss was approximately $1.6M in Q3 and $5.3M for the first nine months; corresponding gross margins were approximately negative 26.5% and negative 32.8%.
- At September 30, cash and cash equivalents were $23.8M, short-term investments $65.6M, long-term investments $14.6M, and restricted cash $0.3M. Total cash and investments, including restricted cash, were $104.3M.
- Total liabilities were $22.4M, including lease liabilities; the filing reports no conventional borrowings. Operating and financing lease liabilities were approximately $7.0M and $0.3M, respectively.
- Cash, cash equivalents, and restricted cash declined $3.3M during the nine months. Investing activities provided $32.1M, mainly reflecting investment maturities exceeding purchases; capital expenditures were $1.4M.
Changes and operating trends
- Quarterly operating loss improved by $2.4M year over year as revenue growth and lower sales and administrative expenses more than offset higher cost of revenue and research and development spending. Higher interest income also contributed to the narrower net loss.
- For the nine months, operating loss improved $1.6M. Product and service costs rose faster than revenue, while interest income increased $2.2M to $3.2M as investment yields rose.
- Management attributed revenue growth to more system placements and consumable shipments, improved customer-site access compared with COVID-affected 2022 periods, and increased service-contract revenue as more systems were validated.
- Five systems were placed and four validated in Q3, versus three placed and four validated a year earlier. Cumulative placements reached 135 and cumulative validations 112.
- Cost of product revenue included temporary manufacturing inefficiency and downtime associated with enhancements to the automated consumables manufacturing line: approximately $0.4M of Q3 cost and $1.2M for the nine-month period, according to management.
Outlook, liquidity, and risks
- No quantified revenue, earnings, or cash-flow guidance is provided. Management expects significant operating losses to continue and says existing cash and investments should fund operating and capital requirements for at least 12 months after the financial statements were issued. The estimate depends on assumptions and capital could be exhausted sooner.
- Management expects to continue investing in sales, manufacturing and service capacity, research and development, and product enhancements. It says future operations may require equity or debt financing; inability to obtain capital could force delays, reductions, or discontinuation of plans.
- Inflation and higher interest rates may increase labor, materials, and freight costs and could weaken customer demand. Revenue may vary with customer budgets, seasonal patterns, system-placement timing, and customer-site access.
- Customer concentration is material: three customers together represented 36.3% of Q3 revenue; one customer represented 18.2% of nine-month revenue. Management reports no significant concentration in any single supplier or manufacturer.
- The company received a Nasdaq minimum-bid-price deficiency notice in September 2023 after its share price stayed below $1 for 30 consecutive business days. It regained compliance after 10 consecutive qualifying days, and Nasdaq closed the matter on September 26.
- Management identified banking-system and financial-market instability as a risk that could affect access to cash and investments. It reported no current material litigation and no pending U.S. tax examinations. A full valuation allowance remains against deferred tax assets.
- The filing refers to exploration of strategic alternatives among possible forward-looking matters but does not provide a specific update or quantified outcome.
Important facts for investors to verify
- Whether revenue growth, system placements, customer validations, and recurring consumables use continue, given validation and adoption timelines.
- Whether manufacturing-line improvements resolve temporary inefficiencies and improve product gross margins.
- Cash burn, investment maturities, and the assumptions supporting management’s stated 12-month liquidity outlook.
- Customer concentration and the effect of any large customer’s ordering or validation delays.
- Potential financing needs, share dilution, and progress—if any—on strategic alternatives.
- Ongoing Nasdaq listing compliance and exposure to financial-market, inflation, and interest-rate risks.